Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

1.5 million children have lost parents to pandemic; potential brain gateway for virus found

Published 07/21/2021, 03:42 PM
Updated 07/21/2021, 03:46 PM
© Reuters. FILE PHOTO: A child looks at the "Naming the Lost Memorials," as the U.S. deaths from the coronavirus disease (COVID-19) are expected to surpass 600,000, at The Green-Wood Cemetery in Brooklyn, New York, U.S., June 10, 2021. REUTERS/Brendan McDermid/File

By Nancy Lapid

(Reuters) - The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19.

1.5 million children lost parents to COVID-19 so far

During the first 14 months of the pandemic, an estimated 1.5 million children worldwide experienced the death of a parent, custodial grandparent, or other relative who cared for them, as a result of COVID-19, according to a study published in The Lancet https:// on Tuesday. The orphanhood estimates are drawn from mortality data from 21 countries that account for 77% of global COVID-19 deaths and from the United Nations Population Division. "For every two COVID-19 deaths worldwide, one child is left behind to face the death of a parent or caregiver," Dr. Susan Hillis from the U.S. Centers for Disease Control and Prevention COVID-19 Response Team, who led the study, said in a statement. The number of COVID-19 orphans will increase as the pandemic progresses, she added. There is an urgent need to prioritize these children and "support them for many years into the future," Hillis said. Said study coauthor Lucie Cluver of Oxford University: "And we need to respond fast because every 12 seconds a child loses their caregiver to COVID-19."

Potential brain gateway found for coronavirus

Researchers have found a potential route of entry for the coronavirus into the human brain that may help explain the effects of COVID-19 on the brain and nervous system that have plagued many patients. To date there is no evidence that the virus directly infects neurons - the brain cells that receive and send messages to and from the body. In a new study, experimenting with an artificially grown mass of cells created to resemble the brain, researchers found that neurons seemed "impervious" to the coronavirus, said Joseph Gleeson of the University of California, San Diego. But cells called pericytes, which wrap around blood vessels and carry the surface protein the virus uses for entry, proved to be a different story. When researchers added pericytes to their artificial brain and then added the virus, "we found incredibly robust infection," not just of the pericytes but also of the neurons, Gleeson said. They report in Nature Medicine https://go.nature.com/3eHmumt that the pericytes served as "factories" for the virus, from which it could multiply. The primary targets were astrocytes, which have crucial roles in regulating the brain's electrical impulses, providing neurons with nutrients, and maintaining the "blood-brain barrier" that shields the brain from foreign substances. The findings, Gleeson said, suggest "pericytes could serve as an entry point for SARS-CoV-2," which could either lead to local increases in the virus or to inflammation of blood vessels that can cause stroke.

Vaccine boosters not yet needed, researchers say

© Reuters. FILE PHOTO: A child looks at the

Two doses of an mRNA vaccine from Pfizer/BioNTech or Moderna (NASDAQ:MRNA) are effective at neutralizing the highly contagious Delta variant of the coronavirus that is or will soon be dominant in most places, suggesting immediate booster doses are not likely needed, researchers said. They did not measure the vaccines' ability to protect against infection in the real world. In their lab experiments using blood samples from vaccinated volunteers, however, Delta's mutations caused only low reductions in the proportion of antibodies that could neutralize the virus, they said. Mutations in the less prevalent Beta and Gamma variants reduced antibody neutralization capacity more significantly, but not to a point where vaccine recipients would appear to be unprotected, the researchers reported on Sunday in a paper posted on medRxiv https:// ahead of peer review. Vaccine boosters may be needed in the future to help overcome some variants, coauthor Akiko Iwasaki of Yale University said in a tweet on Tuesday. Her team also found that overall, neutralizing antibody levels after vaccination were higher in COVID-19 survivors than in uninfected vaccine recipients. "This is not surprising," Iwasaki told Reuters, "because infection itself induces immune responses, which were boosted by the two doses of vaccines."

Click for a Reuters graphic https://tmsnrt.rs/3c7R3Bl on vaccines in development.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.